Chronic heart failure
100 results
1 - 100
Aliskiren not beneficial for chronic heart failure (ATMOSPHERE)- IV iron improves symptoms in chronic heart failure patients with iron deficiency
- Finerenone decreases hospitalization for heart failure in patients with type 2 diabetes and chronic kidney disease (NNT = 189/year)
- Sertraline ineffective for depression associated with heart failure
- BNP-guided therapy decreases heart failure mortality (BATTLESCARRED)
- Point-of-care BNP testing may be helpful to rule out heart failure
- New "-flozin" type 2 diabetes treatments improve outcomes in patients with heart failure, with or without diabetes
- Improved decongestion with the addition of acetazolamide to intravenous loop diuretics for acute heart failure
- Sotagliflozin reduces hospitalizations and urgent visits for heart failure, but has no mortality benefit (SCORED)
- Intravenous iron therapy improves quality of life in iron-deficient adults with heart failure
- Interpreting BNP in patients with a history of HF
- Guideline for the management of heart failure: early prevention for patients at risk, quadruple therapy for those with symptoms
- BNP-guided tx decreases CHF mortality
- Carvedilol not beneficial for children and adolescents with heart failure
- SGLT2 inhibitors ("-flozin" meds) improve all-cause and CV mortality in patients regardless of diabetes or HF status
- Rhythm control improves quality of life in patients with CHF and AF
- Dapagliflozin reduces mortality and hospitalization rates for patients with mild heart failure and reduced ejection fraction
- Minimal, if any, cardiovascular benefit from intravenous iron for adults with heart failure and iron deficiency
- Rosuvastatin has no effect on clinical outcomes in CHF
- Darbepoetin alfa does not improve HF outcomes
- No benefit with torsemide over furosemide for posthospitalization treatment of heart failure (TRANSFORM-HF)
- Beta-blockers don't decrease mortality in patients with AF + CHF
- Acute cardiovascular events are common in patients hospitalized with influenza
- SGLT2 inhibitors, GLP1 agonists provide greater benefit for patients with type 2 diabetes
- Post-MI beta-blockers do not decrease mortality
- In high-risk older patients with atrial fibrillation, rhythm control reduces cardiovascular death and stroke, but at a price
- Taking furosemide on day of surgery does not increase intraop hypotension
- Guidelines suggest new diabetes medicine choice based on cardiovascular and chronic kidney disease risk
- COVID-19 research briefs: case series of critically ill patients in the intensive care unit
- 2022 NICE guidance: type 2 diabetes
- Dapagliflozin reduces mortality and renal replacement in patients with chronic kidney disease
- Greater continuity of care associated with fewer preventable hospitalizations
- Bolus loop diuretics = continuous infusion in treatment of CHF (DOSE trial)
- Treatment of acute hypoxemic respiratory failure with noninvasive ventilation using a helmet or face mask led to fewer deaths
- Treatment with SGLT2 inhibitors rarely results in diabetic ketoacidosis
- CV interventions in old elderly are not useful (DEBATE)
- Decreased hospital LOS not associated with increase in 30-day readmission rates
- Individualizing T2DM goals is paramount, according to experts
- No difference in death or major ischemic events with postop liberal or restrictive postop transfusion (TOP)
- For severe hypoxemia due to chronic obstructive pulmonary disease or pulmonary fibrosis, 24 hours of oxygen is no better than 15 hours
- ACC/AHA guidelines for the diagnosis and management of atrial fibrillation
- More evidence against antibiotics for acute asthma exacerbations
- For patients with chronic kidney disease, prehydration prior to contrast-enhanced computed tomography is unnecessary
- ACC/AHA guideline for the management of patients with chronic coronary disease
- Isolated diastolic hypertension not associated with increased risk of CVD
- JNC 8 report on prevention/evaluation/treatment of hypertension
- No benefit to addition of stenting for treatment of atherosclerotic renal artery stenosis
- Supplementing potassium for patients with implantable cardiac defibrillator and low-normal potassium improves cardiovascular outcomes (POTCAST)
- Higher hemoglobin target with epoeitin alfa is harmful in CKD (CHOIR)
- Adults with varicose veins are at increased risk of DVT
- In adults with medical comorbidities, influenza vaccinations are associated with a lower risk of developing dementia
- Short-term high-flow oxygen therapy for low-risk patients decreases reintubation rates
- Lower costs and healthcare utilization with hospital care at home
- Rosuvastatin does not improve outcomes in HF with average lipids
- Sotrovimab reduces the likelihood of hospitalization in at-risk outpatients with mild to moderate COVID-19 (NNT = 16)
- Higher risk of bleeding events associated with concomitant use of amiodarone and direct oral anticoagulants
- Ipratropium associated with increase risk of CV events
- No decrease in all-cause mortality with LMWH for VTE prophylaxis in hospitalized medical patients
- SBP of 120 instead of 140 in nondiabetic, high-risk elderly leads to significant benefits and some harms (SPRINT)
- SGLT2 inhibitors reduce cardiovascular mortality but benefit is modest, even in patients with established heart disease (NNT = 200 for 3 years)
- Guidelines for obstructive sleep apnea and insomnia from the US Departments of Defense and Veteran Affairs
- Patient navigators reduce readmission rates for high-risk older patients
- Colchicine reduces myocardial infarction and revascularization in patients with established coronary disease (LoDoCo2)
- Apixaban slightly more effective and safe than warfarin, but more expensive
- High-dose influenza vaccine no more effective than the standard dose for adults with high-risk cardiovascular disease
- Two-day oral dexamethasone course effective in treatment of mild asthma exacerbation
- Wells score not helpful in hospitalized patients with suspected DVT
- Liraglutide reduces mortality (NNT = 71) in patients with T2DM and very high CV risk
- Overview of new ACC/AHA lipid guidelines: here we go again
- Clinical, functional, and demographic factors predict 10-year mortality in adults older than 50
- Dronedarone prevents AF recurrence but effect on symptoms unknown